Candriam Luxembourg S.C.A. Has $2,150,000 Position in Bio-Rad Laboratories, Inc. (BIO)

Candriam Luxembourg S.C.A. maintained its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 9,500 shares of the medical research company’s stock at the end of the second quarter. Candriam Luxembourg S.C.A.’s holdings in Bio-Rad Laboratories were worth $2,150,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of BIO. BlackRock Inc. raised its stake in Bio-Rad Laboratories by 9,953.4% in the first quarter. BlackRock Inc. now owns 1,733,111 shares of the medical research company’s stock worth $345,478,000 after buying an additional 1,715,872 shares during the last quarter. Vanguard Group Inc. raised its stake in Bio-Rad Laboratories by 3.6% in the first quarter. Vanguard Group Inc. now owns 1,673,274 shares of the medical research company’s stock worth $333,550,000 after buying an additional 58,774 shares during the last quarter. TimesSquare Capital Management LLC raised its stake in Bio-Rad Laboratories by 17.2% in the first quarter. TimesSquare Capital Management LLC now owns 611,700 shares of the medical research company’s stock worth $121,936,000 after buying an additional 89,800 shares during the last quarter. Alliancebernstein L.P. raised its stake in Bio-Rad Laboratories by 1.7% in the first quarter. Alliancebernstein L.P. now owns 335,197 shares of the medical research company’s stock worth $66,818,000 after buying an additional 5,647 shares during the last quarter. Finally, Fisher Asset Management LLC raised its stake in Bio-Rad Laboratories by 1.9% in the second quarter. Fisher Asset Management LLC now owns 279,589 shares of the medical research company’s stock worth $63,274,000 after buying an additional 5,233 shares during the last quarter. 63.73% of the stock is owned by institutional investors and hedge funds.

Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) opened at 215.00 on Friday. Bio-Rad Laboratories, Inc. has a 12-month low of $147.68 and a 12-month high of $242.79. The company has a market cap of $6.37 billion, a price-to-earnings ratio of 424.90 and a beta of 0.91. The firm has a 50 day moving average price of $229.37 and a 200-day moving average price of $212.18.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Ticker Report and is owned by of Ticker Report. If you are accessing this piece on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this piece can be viewed at https://www.tickerreport.com/banking-finance/2802316/candriam-luxembourg-s-c-a-has-2150000-position-in-bio-rad-laboratories-inc-bio.html.

A number of analysts have commented on BIO shares. Zacks Investment Research lowered Bio-Rad Laboratories from a “hold” rating to a “sell” rating in a report on Thursday. BidaskClub raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Thursday, June 22nd. Jefferies Group LLC reissued a “buy” rating and issued a $275.00 target price on shares of Bio-Rad Laboratories in a report on Friday, July 14th. Wells Fargo & Company started coverage on Bio-Rad Laboratories in a report on Thursday, July 13th. They issued an “outperform” rating and a $250.00 target price for the company. Finally, Deutsche Bank AG raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating and reduced their target price for the stock from $220.00 to $195.00 in a report on Wednesday, June 28th. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $228.80.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO).

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.